Logo Image
|Articles|April 28, 2023

Bas Trietsch Discusses Successes so Far Using Organ on a Chip Technology for Bio/Pharmaceuticals (INTERPHEX 2023)

Bas Trietsch, chief technology officer, MIMETAS, discusses the successes he's encountered so far using organ on a chip technology in bio/pharmaceutical research.

Bas Trietsch, chief technology officer, MIMETAS, and one of the INTERPHEX Keynote speakers in the Organ on a Chip for Pharmaceutical Development session, discusses the successes his company has encountered so far using organ on a chip technology in bio/pharmaceutical research.

For more INTERPHEX 2023 video content, check this page for updates.

Related to this article

View more
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Read more
Trophy and confetti on light background, top view with space for text. Victory concept | Image Credit: ©New Africa -stock.adobe.com
Winners of the 2026 CPHI Pharma Awards Announced
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Read more
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Read more